Equity Profile

MIRM

Mirum Pharmaceuticals, Inc.

Health CareBiotechnology$5.7B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Mirum Pharmaceuticals Misses on EPS, Stock Up 4.04%

Metric	Actual	Expected	Surprise
EPS	$-13.43	$-0.39	-3224.26%
Revenue	$—	$149M	—

management commentary, guidance changes, and full analysis available with Pro.

Mirum Pharmaceuticals Misses on EPS, Stock Up 4.04%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-13.43	$-0.39	-3224.26%
Revenue	$—	$149M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

What It Means

Mirum Pharmaceuticals reported a significant miss on EPS, with actual earnings far below expectations. Despite this disappointing result, the stock reacted positively, increasing by 4.04%. This could indicate that investors are looking beyond the immediate earnings figures, possibly focusing on other aspects of the company's future potential.

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.39

Revenue

Revenue figures will help gauge the company's sales performance and market demand for its products.

$149M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare liver diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for specialized medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q4 2025, Mirum reported an EPS of $-0.47, significantly missing estimates, which led to a modest stock increase the following day. The company did not provide revenue figures, leaving investors uncertain about sales performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Mirum to report a loss of $0.39 per share on revenues of $149 million. Investors are watching closely for any signs of improvement in sales and cost management.

Bull Case

If Mirum can exceed revenue expectations and show a narrower loss than anticipated, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss, it could raise concerns about its growth prospects and market position.

Key Metrics to Watch

EPS

$-0.39

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$149M

Revenue figures will help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Mirum's revenue meet or exceed the consensus estimate of $149 million?

This figure will be crucial in assessing the company's market performance and growth potential.

What is the company's strategy for reducing its EPS loss from the consensus estimate of $-0.39?

Understanding management's approach to improving profitability will be key for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Mirum's potential for revenue growth due to recent product developments that have not been fully factored into analyst models.

Supporting Evidence

Mirum has a history of beating EPS estimates, which could indicate stronger underlying performance.

The options market is pricing a larger move than historical averages, suggesting that traders expect significant news.

Insider selling could indicate a need for caution, but it may not reflect the company's overall growth potential.

Key Risk

If revenue comes in above $155 million, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's trajectory and investor sentiment.

Bull Confirmed If

Revenue exceeding $149 million with an EPS loss narrower than $-0.39 would confirm the bull case.

Bear Confirmed If

Revenue falling below $141 million or an EPS loss greater than $-0.60 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.2%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.5% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

40.2%

Calls (21K)P/C Ratio: 0.09Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests a potential stock increase of around 1.04%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 0.93%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost control measures and their effectiveness.
3Insights into market demand for Mirum's treatments and any competitive pressures.
4Details on any partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.39

Revenue

Revenue figures will help gauge the company's sales performance and market demand for its products.

$149M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Mirum to report a loss of $0.39 per share on revenues of $149 million. Investors are watching closely for any signs of improvement in sales and cost management.

Bull Case

If Mirum can exceed revenue expectations and show a narrower loss than anticipated, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a larger loss, it could raise concerns about its growth prospects and market position.

Key Metrics to Watch

EPS

$-0.39

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$149M

Revenue figures will help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Mirum's revenue meet or exceed the consensus estimate of $149 million?

This figure will be crucial in assessing the company's market performance and growth potential.

What is the company's strategy for reducing its EPS loss from the consensus estimate of $-0.39?

Understanding management's approach to improving profitability will be key for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Mirum's potential for revenue growth due to recent product developments that have not been fully factored into analyst models.

Supporting Evidence

Mirum has a history of beating EPS estimates, which could indicate stronger underlying performance.

The options market is pricing a larger move than historical averages, suggesting that traders expect significant news.

Insider selling could indicate a need for caution, but it may not reflect the company's overall growth potential.

Key Risk

If revenue comes in above $155 million, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining the company's trajectory and investor sentiment.

Bull Confirmed If

Revenue exceeding $149 million with an EPS loss narrower than $-0.39 would confirm the bull case.

Bear Confirmed If

Revenue falling below $141 million or an EPS loss greater than $-0.60 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.2%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.5% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

40.2%

Calls (21K)P/C Ratio: 0.09Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests a potential stock increase of around 1.04%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 0.93%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost control measures and their effectiveness.
3Insights into market demand for Mirum's treatments and any competitive pressures.
4Details on any partnerships or collaborations that could enhance growth prospects.